Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression - Aix-Marseille Université Accéder directement au contenu
Article Dans Une Revue iScience Année : 2021

Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression

Résumé

Metabolic heterogeneity within the tumor microenvironment promotes cancer cell growth and immune suppression. We determined the impact of mitochondria-targeted complex I inhibitors (Mito-CI) in melanoma. Mito-CI decreased mitochondria complex I oxygen consumption, Akt-FOXO signaling, blocked cell cycle progression, melanoma cell proliferation and tumor progression in an immune competent model system. Immune depletion revealed roles for T cells in the antitumor effects of Mito-CI. While Mito-CI preferentially accumulated within and halted tumor cell proliferation, it also elevated infiltration of activated effector T cells and decreased myeloid-derived suppressor cells (MDSC) as well as tumor-associated macrophages (TAM) in melanoma tumors in vivo. Anti-proliferative doses of Mito-CI inhibited differentiation, viability, and the suppressive function of bone marrow-derived MDSC and increased proliferation-independent activation of T cells. These data indicate that targeted inhibition of complex I has synchronous effects that cumulatively inhibits melanoma growth and promotes immune remodeling.

Domaines

Chimie
Fichier principal
Vignette du fichier
pub1mica2021.pdf (4.12 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03627837 , version 1 (01-04-2022)

Licence

Identifiants

Citer

Mahmoud Abueid, Donna Mcallister, Laura Mcolash, Megan Harwig, Gang Cheng, et al.. Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression. iScience, 2021, 24 (6), pp.102653. ⟨10.1016/j.isci.2021.102653⟩. ⟨hal-03627837⟩
20 Consultations
34 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More